NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

NovoCure Limited (NVCR) Stock Analysis

NovoCure Limited (NVCR) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

NVCR

$17.94

+$0.30 (+1.70%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NVCR with… →

NVCR Key Statistics

As of Sep 4, 2026
Trading
Open
$17.53
Previous Close
$17.64
Day's Range
17.47–18.02
52-Week Range
9.82–21.45
Volume
732.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.01
Valuation
Market Cap
$2.09B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.99
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.30
Financials (FY)
Revenue (FY)
$655.35M+8.28%
Net Income (FY)
−$136.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
−21.25%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
116.45M
1-Year Return
+49.75%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
1.60M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NVCR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+38.75%
2025−56.61%
2024+99.60%
2023−79.65%
2022−2.30%
2021−56.61%
2020+105.34%
2019+151.70%
2018+65.74%
2017+157.32%
2016 (partial year)+3.56%

As of September 4, 2026.

NVCR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$655.35M−$136.23M−20.8%
2024$605.22M−$168.63M−27.9%
2023$509.34M−$207.04M−40.6%
2022$537.84M−$92.53M−17.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$655.35M$488.47M−$153.80M−$136.23M−20.8%
2024$605.22M$468.04M−$170.50M−$168.63M−27.9%
2023$509.34M$381.06M−$232.87M−$207.04M−40.6%
2022$537.84M$422.97M−$89.52M−$92.53M−17.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NVCR Valuation vs Medical Devices Median

Median of 151 stocks
MetricNVCRMedical Devices medianvs median
P/S ratio2.992.980% above
Profit margin−21.25%−1.69%19.6 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values NovoCure Limited (NVCR) at $2.09B. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 1,605.

NVCR last closed at $17.94 on September 4, 2026. That is +$0.30 (+1.70%) against the previous close. The 52-week range on file runs from $9.82 to $21.45. The latest close sits 82.69% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $655.35M. Against the prior fiscal year total of $605.22M, that is a change of +8.28%. The same year closed with a net loss of $136.23M. The reported profit margin is −21.25%. That is 19.6 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −1.3.

Across the 4 fiscal years on file, revenue moves from $537.84M in 2022 to $655.35M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 2.99 times revenue. On price-to-sales that is 0.39% above the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The trailing one-year price return is +49.75%. Measured over 10 years, that is +8.34% a year compounded. Beta against the wider market is reported at 1.01. Annualized volatility over the trailing 10 years is 72.27%.

Growth & Income

No dividend is on file for NVCR.

The strongest complete calendar year on file is 2017 at +157.32%; the weakest is 2023 at −79.65%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +38.75% year to date.

Peer Comparison

NovoCure Limited (NVCR) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NovoCure Limited NVCR $2.09B —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. NovoCure Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Visit website →